BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 32116148)

  • 1. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
    Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
    Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow fever vaccine protects mice against Zika virus infection.
    Vicente Santos AC; Guedes-da-Silva FH; Dumard CH; Ferreira VNS; da Costa IPS; Machado RA; Barros-Aragão FGQ; Neris RLS; Dos-Santos JS; Assunção-Miranda I; Figueiredo CP; Dias AA; Gomes AMO; de Matos Guedes HL; Oliveira AC; Silva JL
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009907. PubMed ID: 34735450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine.
    Giel-Moloney M; Goncalvez AP; Catalan J; Lecouturier V; Girerd-Chambaz Y; Diaz F; Maldonado-Arocho F; Gomila RC; Bernard MC; Oomen R; Delagrave S; Burdin N; Kleanthous H; Jackson N; Heinrichs J; Pugachev KV
    Sci Rep; 2018 Sep; 8(1):13206. PubMed ID: 30181550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.
    Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A
    J Virol; 2020 May; 94(10):. PubMed ID: 32132233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice.
    Kum DB; Mishra N; Boudewijns R; Gladwyn-Ng I; Alfano C; Ma J; Schmid MA; Marques RE; Schols D; Kaptein S; Nguyen L; Neyts J; Dallmeier K
    NPJ Vaccines; 2018; 3():56. PubMed ID: 30564463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Infections of Zika, Dengue, and Yellow Fever Viruses in Human Cytotrophoblast-Derived Cells Suggest a Gating Role for the Cytotrophoblast in Zika Virus Placental Invasion.
    Viettri M; Caraballo G; Sanchez ME; Espejel-Nuñez A; Betanzos A; Ortiz-Navarrete V; Estrada-Gutierrez G; Nava P; Ludert JE
    Microbiol Spectr; 2023 Jun; 11(3):e0063023. PubMed ID: 37227282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
    Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
    J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses.
    Neves PC; Santos JR; Tubarão LN; Bonaldo MC; Galler R
    PLoS One; 2013; 8(12):e81953. PubMed ID: 24324734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
    Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
    Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.
    Schäfer B; Holzer GW; Joachimsthaler A; Coulibaly S; Schwendinger M; Crowe BA; Kreil TR; Barrett PN; Falkner FG
    PLoS One; 2011; 6(9):e24505. PubMed ID: 21931732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.
    Watson AM; Lam LK; Klimstra WB; Ryman KD
    PLoS Pathog; 2016 Jul; 12(7):e1005786. PubMed ID: 27463517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
    Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
    Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
    Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.
    Tretyakova I; Nickols B; Hidajat R; Jokinen J; Lukashevich IS; Pushko P
    Virology; 2014 Nov; 468-470():28-35. PubMed ID: 25129436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine.
    Lima NS; Moon D; Darko S; De La Barrera RA; Lin L; Koren MA; Jarman RG; Eckels KH; Thomas SJ; Michael NL; Modjarrad K; Douek DC; Trautmann L
    Front Immunol; 2021; 12():640190. PubMed ID: 33717194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.
    Ma J; Boudewijns R; Sanchez-Felipe L; Mishra N; Vercruysse T; Buh Kum D; Thibaut HJ; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2021 Dec; 10(1):2279-2290. PubMed ID: 34792431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
    Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
    J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.